RxDoctor Payments Data

Young-Ki Paik, MD

Internal Medicine · Port Orchard, WANPI 1437314614

Payments from drug & device makers

$359in general payments, 2019–2025

Across 19 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$66
  • GSK$60
  • Pfizer$47
  • Novartis$38
  • Novo Nordisk$31
  • Boehringer Ingelheim$26
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$359 in reported general payments places this provider in the 80th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$372,949
Medicare patients
461
Services billed
6,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$97,261
JardianceEmpagliflozin61$71,361
XareltoRivaroxaban51$62,136
RybelsusSemaglutide26$42,313
OzempicSemaglutide18$40,671
JanuviaSitagliptin Phosphate28$25,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,638
FarxigaDapagliflozin Propanediol16$23,508
Atorvastatin Calcium722$7,149
MyrbetriqMirabegron12$5,358
PaxlovidNirmatrelvir/Ritonavir15$4,287
Omeprazole272$4,146
Tamsulosin Hcl215$4,093
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$4,036
Levothyroxine Sodium246$3,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$47$101,54895 claims
Novo NordiskRybelsus, Ozempic$31$82,98344 claims
Boehringer IngelheimJardiance$26$71,36161 claims
GSKTrelegy Ellipta$60$24,63834 claims
AstraZenecaFarxiga$17$23,50816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Port Orchard

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →